Literature DB >> 8872967

Immunoglobulin-A and the pathogenesis of schistosomal glomerulopathy.

R Barsoum1, M Nabil, G Saady, C Genin, E Saleh, M Francis, A el-Kalioubi, I Iskander, A el-Garem.   

Abstract

Several observations suggest that the evolution of schistosomal glomerulopathy into clinically overt and progressive disease may involve pathogenetic mechanisms other than simple glomerular deposition of parasitic antigens. In a previous study, IgA was suggested to be a mediator of late glomerular lesions in this disease. This issue is further addressed in this work. The study includes 32 patients with hepatosplenic schistosomiasis, of whom 16 had overt glomerular involvement, along with four control groups: (a) 15 healthy volunteers; (b) 15 patients with simple intestinal mansoniasis; (c) 17 patients with non-schistosomal chronic liver disease; and (d) 21 subjects with primary nephrotic syndrome not associated with schistosomiasis. Routine assessment was done for all subjects including confirmatory tests for schistosomal infection, liver and renal function tests, hepatitis viral markers and abdominal ultrasonography. The total serum concentrations of IgG, IgM, IgA were measured, as well as their respective circulating immune complexes, rheumatoid factors, anti-gliadin- and anti-DNA-antibodies. Liver and renal biopsies were obtained from the relevant groups and studied by light microscopy. Renal biopsies were also examined by immunofluorescence. Patients with simple intestinal schistosomiasis had a significant increase in IgM antigliadin antibodies. Those complicated with hepatosplenic involvement also had a significant increase in the mean IgG anti-gliadin antibodies, IgG rheumatoid factor and IgM anti-DNA activity. Cases further complicated by overt glomerular disease showed a distinct IgA predominance, mainly expressed in the serum anti-gliadin antibody pool and anti-DNA activity. This profile was essentially similar to that observed in control cirrhotics. There was a significant increase in the frequency of IgA glomerular deposits in renal biopsies obtained from patients with overt schistosomal glomerulopathy, in contrast to control nephrotics. The deposits were mainly mesangial, but were also encountered in subendothelial, subepithelial and peritubular locations. Their frequency was significantly higher with more advanced lesions as seen by light microscopy. The relevance of these data is discussed, leading to the following conclusions: (a) serum IgA-anti-gliadin and -anti-DNA antibodies, and glomerular IgA deposits are markers of significant renal involvement in patients with hepatosplenic schistosomiasis. (b) IgA may be involved in the pathogenesis of advanced glomerular pathology when superimposed on parasite-induced lesions. (c) There is a significant increase in serum auto-reactivity in hepatosplenic schistosomiasis, which may also have pathogentic implications. (d) Increased production by the inflammatory bowel lesions, impaired clearance by the fibrotic livers and probable switching of immunoglobulin synthesis are suggested to explain the observed IgA predominance in those who develop renal complications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872967     DOI: 10.1038/ki.1996.392

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

1.  Schistosoma hematobium-associated glomerulopathy.

Authors:  S M Seck; M L Sarr; M C Dial; E F Ka
Journal:  Indian J Nephrol       Date:  2011-07

2.  Renal function in hepatosplenic schistosomiasis--an assessment of renal tubular disorders.

Authors:  Daniella Bezerra Duarte; Lucas Alexandre Vanderlei; Raianne Kívia de Azevêdo Bispo; Maria Eliete Pinheiro; Geraldo Bezerra da Silva; Alice Maria Costa Martins; Gdayllon Cavalcante Meneses; Elizabeth De Francesco Daher
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

Review 3.  Urinary schistosomiasis: review.

Authors:  Rashad S Barsoum
Journal:  J Adv Res       Date:  2012-11-05       Impact factor: 10.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.